- Home
- IPSC
as 05-20-2024 10:33am EST
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | PHILADELPHIA |
| Market Cap: | 248.5M | IPO Year: | 2021 |
| Target Price: | $13.67 | AVG Volume (30 days): | 189.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.28 - $5.51 | Next Earning Date: | 05-09-2024 |
| Revenue: | $1,370,000 | Revenue Growth: | -76.63% |
| Revenue Growth (this year): | 174.41% | Revenue Growth (next year): | 228.89% |
Share on Social Networks:
Stock Insider Trading Activity of Century Therapeutics Inc. (IPSC)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Russotti Gregory | IPSC | See Remarks | May 6 '24 | Sell | $3.12 | 5,000 | $15,619.00 | 292,319 | SEC Form 4 |
| Farid Adrienne | IPSC | Chief Operations Officer | Feb 16 '24 | Sell | $4.86 | 485 | $2,358.26 | 114,149 | SEC Form 4 |
| Farid Adrienne | IPSC | Chief Operations Officer | Feb 5 '24 | Sell | $3.84 | 2,035 | $7,816.44 | 115,933 | SEC Form 4 |
| Farid Adrienne | IPSC | Chief Operations Officer | Feb 5 '24 | Sell | $4.49 | 1,784 | $8,004.81 | 114,149 | SEC Form 4 |
Latest Century Therapeutics Inc. News
IPSC Breaking Stock News: Dive into IPSC Ticker-Specific Updates for Smart Investing
GuruFocus.com
10 days ago
Century Therapeutics Inc (IPSC) Q1 2024 Earnings: Aligns with EPS Projections Amid Strategic ...
GlobeNewswire
10 days ago
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
Zacks
11 days ago
Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates
GlobeNewswire
11 days ago
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
a month ago
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
BioPharma Dive
a month ago
Century buys a startup, raises funding in cell therapy expansion
GlobeNewswire
a month ago
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
GlobeNewswire
a month ago